-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
IASLC Small Cell Lung Cancer Workshop
Posted: April 2017 By Kristina Wasson-Blader, PhD, ELS International Association for the Study of Lung Cancer (IASLC) hosted the second Small Cell Lung Cancer Workshop at Memorial Sloan Kettering Cancer Center in New York, New York, which is held on an every-other-year basis. This focused meeting attracted more than 175 leading basic scientists and clinical…
-
Interview with Dara Corrigan, JD: United States to Implement Mutual Recognition Agreement with European Union
Posted: April 2017 *Erik T. MacLaren, PhD, is acknowledged for his editorial support of this article. On March 2, 2017, the European Union (EU) and the US announced the Mutual Recognition Agreement to allow the FDA and the EU to accept one another’s inspections of drug and pharmaceutical manufacturing facilities, a change intended to reduce…
-
17th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting
Posted: April 2017 By Kristina Wasson-Blader, PhD, ELS For the 17th year, leading experts in the biology, diagnosis, and treatment of lung cancer convened in Santa Monica, California, from February 22nd to 25th to attend the Targeted Therapies of the Treatment of Lung Cancer meeting. “This important meeting brings lung cancer experts from around the…
-
Should Physicians Recommend E-Cigarettes to Their Lung Cancer Patients Who Smoke? What About Their Family Members Who Also Smoke?
Posted: April 2017 Opinion-No: Emily Stone, MBBS, MMed There is little doubt that lung cancer patients and the people around them who smoke need to stop. Smoking cessation can improve survival,1 surgical outcomes,2-4 and response to anticancer therapies5 and can reduce the risk of recurrence.6 However, many physicians feel poorly trained and unsure about providing…
-
Lung Cancer in the Context of a Precision Medicine Approach
Posted: April 2017 By Giorgio Vittorio Scagliotti, MD, PhD The ambition to personalize medicine is intrinsic to the mission of every individual physician with the twin goals of reducing drug-related toxic effects and improving treatment efficacy. Hippocrates first proposed a combined assessment of the 4 humors—blood, phlegm, yellow bile, and black bile—to determine the best…
-
Societies Join Forces to Host Seventh European Lung Cancer Conference
For the seventh year, the world’s leading societies in the field of thoracic oncology are collaborating to host the European Lung Cancer Conference (ELCC), a multidisciplinary event that aims to advance science, disseminate education, and improve lung cancer care worldwide. The conference, to be held May 5–8 in Geneva, Switzerland, will be hosted by IASLC…
-
Is Tobacco-Free by 2030 a Realistic Goal? The Finnish Government Thinks So
Posted: April 2017 By Cynthia L. Kryder, MS Tobacco exposure remains one of the leading preventable causes of premature disease and death in the United States and abroad. Around the world, 6 million people die each year as a result of tobacco exposure, including 480,000 people in the United States. The global costs of smoking…
-
Thomas J. Lynch Jr, MD
Thomas J. Lynch Jr was appointed executive vice president and chief scientific officer of Bristol- Myers Squibb. Previous to this appointment, Dr. Lynch served as chairman and chief executive officer of Massachusetts General Physicians Organization and as a member of the MGH Board. Prior to that Dr. Lynch was the director of Yale Cancer Center and…
-
Mary Hesdorffer, RN, Nurse Practitioner
Mary Hesdorffer will retire as Executive Director of the Mesothelioma Applied Research Foundation (Meso Foundation) in July 2017. Prior to being Executive Director, Ms. Hesdorffer held several roles with the Mesothelioma Foundation since its inception and following her retirement will continue in an advisory role. She also will also continued to serve on a number of…
-
Shirish M. Gadgeel, MD
Shirish M. Gadgeel has been appointed Professor, Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan as of May 1, where he will be Leader of the Thoracic Oncology Research Program. Dr. Gadgeel will hold the Mary Lou Kennedy Research Professorship in Thoracic Oncology. Previous to this appointment, Dr. Gadgeel was Professor and Leader of…